Fig. 8From: Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)RFS according to PIK3CA/AKT/mTOR pathway status. Kaplan-Meier estimates of RFS according to PIK3CA/AKT/mTOR pathway status in patients; 54 patients with at least 1 mutation in the PIK3CA/AKT/mTOR pathway, 35 patients with no mutation in the PIK3CA/AKT/mTOR pathwayBack to article page